Additionally, down-regulation of TG2 by gene-specific siRNA, antisense RNA or ribozyme approaches reverses drug-resistance in breast, pancreatic, lung, and ovarian carcinoma cells [17-22]. This evidence concerns the gene TGM2 and ovarian carcinoma.